HC Wainwright Has Bearish Estimate for BioNTech Q3 Earnings

BioNTech SE Sponsored ADR (NASDAQ:BNTX) – Equities research analysts at HC Wainwright cut their Q3 2025 earnings per share estimates for shares of BioNTech in a research note issued on Thursday, August 14th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($1.61) for the quarter, down from their prior forecast of ($1.12). HC Wainwright currently has a “Buy” rating and a $136.00 target price on the stock. The consensus estimate for BioNTech’s current full-year earnings is ($3.88) per share. HC Wainwright also issued estimates for BioNTech’s Q4 2025 earnings at ($1.43) EPS, FY2025 earnings at ($6.90) EPS, Q1 2026 earnings at ($2.76) EPS, Q2 2026 earnings at ($2.80) EPS, Q3 2026 earnings at ($1.41) EPS, Q4 2026 earnings at $0.26 EPS and FY2026 earnings at ($6.70) EPS.

BNTX has been the subject of a number of other research reports. Morgan Stanley increased their target price on BioNTech from $132.00 to $133.00 and gave the company an “overweight” rating in a report on Thursday, July 10th. JPMorgan Chase & Co. reduced their price target on shares of BioNTech from $120.00 to $116.00 and set a “neutral” rating on the stock in a research report on Thursday, May 22nd. The Goldman Sachs Group began coverage on BioNTech in a report on Thursday, May 29th. They issued a “neutral” rating and a $110.00 price objective on the stock. Leerink Partners set a $112.00 price target on BioNTech in a research report on Monday, June 2nd. Finally, Bank of America raised their price target on BioNTech from $126.00 to $134.00 and gave the stock a “buy” rating in a research report on Tuesday, August 5th. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $135.80.

BioNTech Price Performance

NASDAQ:BNTX opened at $113.52 on Monday. The stock has a 50 day moving average of $109.42 and a two-hundred day moving average of $105.70. BioNTech has a 12 month low of $81.20 and a 12 month high of $131.49. The firm has a market cap of $27.29 billion, a P/E ratio of -70.95 and a beta of 1.23. The company has a current ratio of 8.61, a quick ratio of 8.48 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Monday, August 4th. The company reported ($1.60) EPS for the quarter, missing analysts’ consensus estimates of ($1.41) by ($0.19). The business had revenue of $306.46 million for the quarter, compared to analyst estimates of $161.26 million. BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. BioNTech’s revenue was up 102.6% on a year-over-year basis. During the same quarter last year, the business earned ($3.36) earnings per share.

Hedge Funds Weigh In On BioNTech

Large investors have recently bought and sold shares of the business. Rhenman & Partners Asset Management AB increased its position in shares of BioNTech by 0.3% during the second quarter. Rhenman & Partners Asset Management AB now owns 35,870 shares of the company’s stock worth $3,819,000 after purchasing an additional 120 shares in the last quarter. Kennedy Capital Management LLC increased its position in BioNTech by 0.8% during the 2nd quarter. Kennedy Capital Management LLC now owns 16,422 shares of the company’s stock worth $1,748,000 after purchasing an additional 127 shares during the period. Profund Advisors LLC increased its position in BioNTech by 3.6% during the 2nd quarter. Profund Advisors LLC now owns 4,309 shares of the company’s stock worth $459,000 after purchasing an additional 149 shares during the period. Probity Advisors Inc. increased its position in BioNTech by 8.5% during the 4th quarter. Probity Advisors Inc. now owns 1,970 shares of the company’s stock worth $224,000 after purchasing an additional 154 shares during the period. Finally, Banco Bilbao Vizcaya Argentaria S.A. lifted its position in shares of BioNTech by 2.5% during the 2nd quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 7,653 shares of the company’s stock valued at $822,000 after acquiring an additional 186 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.